| 11/25/2025 | EULM | Merck wraps subordinated notes tender offer with €571 million response
|
| 11/18/2025 | EULM | Merck launches, upsizes tender offer for subordinated notes due 2080
|
| 11/17/2025 | EUIG | S&P gives BBB+ to Merck hybrids
|
| 8/15/2025 | IG | Market Commentary: M&A-related deals rise in high-grade market; August supply to slow; ETF inflows surge
|
| 8/13/2025 | IG | New Issue: Merck’s EMD prices $4 billion of notes due 2028, 2030, 2032 and 2035
|
| 8/11/2025 | IG | S&P rates EMD Finance notes A
|
| 10/1/2024 | EULM | Merck calls subordinated fixed-to-reset notes due 2074, 2079
|
| 8/20/2024 | EUIG | Moody's assigns Baa2 to Merck hybrids
|
| 9/7/2022 | EULM | Merck accepts tenders for €249.4 million 2079 notes in two-series offer
|
| 8/31/2022 | EULM | Merck begins tender offer for up to €250 million notes from two series
|
| 4/4/2022 | EULM | Merck to redeem €550 million 1.375% notes due 2022
|
| 10/21/2021 | IG | Moody's upgrades Merck
|
| 9/9/2020 | EULM | Merck accepts tenders for €683.12 million of notes due 2074
|
| 9/3/2020 | IG | S&P rates Merck KGaA notes BBB+
|
| 6/18/2019 | IG | S&P rates Merck notes BBB+
|
| 7/13/2018 | IG | Moody’s affirms Merck at Baa1
|
| 10/11/2016 | IG | S&P revises Merck view to stable
|
| 8/30/2016 | IG | Moody’s changes Merck to stable
|
| 3/16/2015 | EMHYMUPFPV | Market Commentary: Market shows signs of indigestion; Merck, APT price; Bank, financial paper flat; Exxon weak
|
| 3/16/2015 | IG | Market Commentary: Market shows signs of indigestion; Merck, APT price; Bank, financial paper flat; Exxon weak
|
| 3/16/2015 | IG | New Issue: Merck prices $4 billion of senior notes in five maturities
|
| 3/16/2015 | IG | Merck talks benchmark five-part bond offering for Monday pricing
|
| 12/12/2014 | IG | Moody’s downgrades Merck to Baa1
|
| 12/2/2014 | IG | S&P provides BBB+ to Merck notes
|
| 12/1/2014 | IG | Moody’s assigns Baa3 to Merck notes
|
| 9/24/2014 | IG | S&P lowers Merck to negative
|
| 9/23/2014 | IG | Moody's might downgrade Merck
|
| 9/22/2014 | BKBWIG | Merck to use loans, bonds to fund $17 billion Sigma-Aldrich acquisition
|
| 7/5/2013 | IG | Moody's upgrades Merck
|
| 12/19/2012 | CVIG | Moody's upgrades Merck
|
| 6/26/2012 | CVHYIG | Moody's: Merck positive
|
| 7/27/2010 | CVHYLM | Millipore 3.75%, 5.875% noteholders get change-of-control put option
|
| 7/16/2010 | IG | Moody's drops Merck
|
| 3/5/2010 | IG | Market Commentary: Masco sells split-rated bonds, coming week seen busy; Masco gains, recent new deals firm
|
| 3/1/2010 | IG | Merck to sell bonds to help finance $7.2 billion Millipore acquisition
|
| 9/30/2008 | SS | Market Commentary: Huntsman hangs on to Hexion deal; Wachovia still selling; ImClone's secret admirer stays secret
|
| 9/23/2008 | SS | Market Commentary: Investors watch WaMu; Icahn fights for ImClone; Longs Drug Stores readies for Walgreen hostile bid
|
| 5/14/2007 | SS | Mylan Laboratories to acquire Merck Generics for $6.7 billion in cash
|
| 10/11/2006 | BT | S&P: Pharmaceutical sales growth spurs mergers
|
| 9/21/2006 | BT | Merck to acquire majority shares of Serono for CHF 16.6 billion
|
| 9/21/2006 | BT | S&P puts Merck on watch
|
| 9/21/2006 | BT | Moody's may downgrade Merck
|
| 9/13/2006 | BT | Merck: New recommendations call for metformin at diagnosis of type 2 diabetes
|
| 8/30/2006 | BT | Market Commentary: AnorMED snubs Genzyme bid; PDL higher as Roche backs out; Vasogen zooms 42%; Adeza up
|
| 7/20/2006 | BT | Merck KGaA pays ImClone €7.5 million to sublicense Erbitux
|
| 7/17/2006 | BT | Glenmark, Merck to co-develop, market dermatological products for European market
|
| 6/20/2006 | BT | EMD Pharmaceuticals files NDA for cyanide poisoning treatment
|
| 6/14/2006 | BT | Bayer to buy Merck's 21.8% stake in Schering at €89, Bayer drops lawsuit
|
| 4/3/2006 | BT | Merck receives European approval for Erbitux in head and neck cancer
|
| 3/31/2006 | BT | S&P affirms Merck, off watch
|
| 3/31/2006 | BT | Moody's confirms Merck
|
| 3/14/2006 | BT | Moody's may downgrade Merck
|
| 3/13/2006 | BTCV | S&P puts Merck, Schering on negative watch
|
| 3/13/2006 | BT | Merck announces €14.6 billion takeover offer for Schering
|
| 1/26/2006 | BT | Merck assumes development costs of Biomira's cancer vaccine
|
| 11/28/2005 | BT | S&P rates Merck Finanz bond BBB+
|
| 11/21/2005 | BT | Moody's rates Merck bonds Baa1
|
| 10/24/2005 | BT | Monogram teams with Merck KGaA on Erbitux cancer study
|
